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Teratologic Evaluation of Ethylene Glycol
Monobutyl Ether in Fischer 344 Rats and
New Zealand White Rabbits Following
Inhalation Exposure
by Rochelle W. TyI,* Guillermo Millicovsky,*t Darol E. Dodd,*
Irvin M. Pritts,* Kathryn A. France* and Louan C. Fisher*
Timed-pregnant Fischer 344 rats and New Zealand White rabbits were exposed to ethylene glycol
monobutyl ether vapors by inhalation on gestational days 6 through 15 (rats) or 6 through 18 (rabbits) at
concentrations of 0, 25, 50, 100 or 200 ppm. The animals were sacrificed on gestational day 21 (rats) or 29
(rabbits). In rats, exposure to 200 or 100 ppm resulted in maternal toxicity (clinical signs, decreased body
weight and weight gain, decreased absolute and relative organ weights, decreased food and water
consumption and evidence of anemia), embryotoxicity (increased number of totally resorbed litters and
decreased number ofviable implantations per litter) and fetotoxicity (reductions in skeletal ossification).
No increase in fetal malformations was observed in any exposure grouprelative tocontrols. At 50 or25 ppm,
there was no maternal, embryo or fetal toxicity (including malformations) in rats. In rabbits, exposure to
200 ppm resulted in maternal toxicity (apparent exposure-related increases in deaths and abortions,
clinical signs, decreased weight during exposure and reduced gravid uterine weight at sacrifice) and
embryotoxicity (reduced number of total and viable implantations per litter). No treatment-related
fetotoxicity was seen. No treatment-related increases in fetal malformations orvariations were seen at any
exposure concentration tested. There was no evidence of maternal, embryo, or fetal toxicity (including
malformations) at 100, 50 or 25 ppm in rabbits.
Introduction
As part of a program evaluating the potential toxicity
of ethylene glycol monobutyl ether (EGBE), studies
were initiated to evaluate the teratogenic potential of
EGBE in test animals under the sponsorship of the
Chemical Manufacturers Association Glycol Ethers
Program Panel. The initial rat studyemployed exposure
of timed-pregnant Fischer 344 rats to EGBE at 300,
200, or 100 ppm orto 0 ppm (aircontrol) for6 hr perday
during gestational days 6 through 15. Maternal clinical
signs, food and water consumption, and body weights
were recorded. Animals were sacrificed on gestational
day 21 after obtaining blood samples for clinical hema-
tology. Following a complete ovarian and uterine
examination, all live fetuses were weighed, sexed, and
examined externally. Approximately one-half of the
fetuses in each litter were examined for visceral and
craniofacial abnormalities, and the remaining fetuses
were examined for skeletal abnormalities.
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Exposures to 100, 200 and 300 ppm EGBE produced
statistically significant reductions in maternal body
weight gain and food consumption. Water consumption
was reduced during exposure at 300 or 200 ppm. Signs
of maternal toxicity (decrease in red blood cell count;
ocular, nasal, and urogenital discharges; hypoactivity;
etc.) were observed predominantly at 300 and 200 ppm
ofEGBE. One animal exposed to 300 ppm EGBE died.
Exposures to 300 ppm EGBE resulted in an increased
incidence ofembryo and fetalmortality (16 of23 females
pregnant at sacrifice had 100% resorptions at 300 ppm).
No treatment-related fetal external or skeletal malfor-
mations were noted at any concentration of EGBE.
Visceral examinations revealed cardiovascular defects,
specifically ventricular septal defect in two fetuses in
two litters (out of seven litters examined) at 300 ppm
and one fetus in one litter at 100 ppm. These findings
were not statistically significant relative to controls.
Incidence of absent and/or severely shortened innomi-
nate artery, considered variations, was significantly
elevated at 300 ppm relative to controls. Craniofacial
examination offetuses revealed a concentration-related
incidence of enlarged lateral ventricles of the brain,TYL ET AL.
considered avariationindicative ofembryo/fetaltoxicity,
at all concentrations of EGBE. Results from the skel-
etal examinations included concentration-related in-
creases in the incidence of extra ribs (fourteenth,
rudimentary, considered a variation), significant only at
300 ppm, and in the incidence ofreduced ossification in
those skeletal districts indicative offetal toxicity at 200
and 300 ppm, relative to controls.
Since the exposure employed in this initial study
produced maternal and fetal toxicity at all exposure
concentrations, did not identify a "no observable effect
level" (NOEL), and excessive embryo/fetal loss was
observed at 300 ppm, another rat study and a
teratogenic evaluation of EGBE in another mammalian
species were undertaken. This report details the evalua-
tion of EGBE for teratogenic potential in Fischer 344
rats and New Zealand White rabbits.
Materials and Methods
Generation of Atmospheres and
Chamber Parameters
A 55-gal container of EGBE test material (Lot
Number 5804213, BRRC Sample Number 45-235) was
received from Union Carbide Corporation on July 30,
1982. Test material from the original container was
placedin 1 galglassbottlesand blanketedwithnitrogen.
The purity and stability were verified by gas chromato-
graphic analysis both before and after the study. No
significant compositional changes occurred while the
study progressed. The test material remained 99.6%
EGBE throughout the study. Fisher certified hexanes
was used as the solvent for preparation of standards.
The gases for the chromatograph were obtained from
Linde Corporation. The nitrogen and hydrogen were
Ultra High Purity grade and the air was breathing
quality.
A Perkin-Elmer Model 3920B gas chromatograph
(GC) equipped with aflame ionization detectorwas used
to monitor the EGBE vapor concentrations in the
chambers. The GC column was a 6-ft x 4 mm (internal
diameter) glass column packed with 0.15% Fluorad
FC431 (3M Company, St. Paul, MN) on glass beads,
80-120 mesh. A Spectra-Physics series 4000 central
processor, a data interface, and a Perkin-Elmer auto-
matic gas sampling system (station and valve pro-
grammer units and a gas sampling valve) were used
for the analyses.
Calibration of the gas chromatograph was done with
liquid injections of standard solutions of EGBE in
hexanes prepared volumetrically. The series ofstandard
solutionsencompassed the entire range ofvapor concen-
trations generated in the exposure chambers. A linear
calibration curve was obtained when areas (integration
counts) were plotted versus the gas equivalent concen-
trations of the standards. The calibration factor (KF)
was calculated as the ratio between areaA and concen-
tration C:
KF = A/C
The mean KF for all valid injections of standards was
used in subsequent microprocessor calculations. This
calibration factor was checked at least once each week
during the exposure period and did not require
adjustment.
Each chamber atmosphere was analyzed for EGBE
approximately once every hour during each 6-hr expo-
sure. Daily nominal concentrations (an estimated con-
centration calculated from the amount of test material
delivered and the chamber airflow during the exposure
period) were also calculated for each chamber.
Liquid EGBE was metered from a piston pump into a
heated glass evaporator similar in design as described
by Carpenter et al. (1). The temperature in the evapo-
rator was maintained at the lowest level sufficient to
vaporize the liquid. The resultant vapor was carried
into the chamber by passage ofconditioned air through
theevaporator. ChamberatmospherescontainingEGBE
were filtered before leaving an exhaust stack.
The five chambers employed in this study were
rectangular in shape, constructed ofglass and stainless
steel (Wahmann Manufacturing Company, Timonium,
MD), and measured approximately2.1 m x 1 m x 2.1 m
(height). Total volume in each chamber was approxi-
mately 4350 L. An orifice plate was positioned in the
exhaust duct of the chamber and was connected to a
Dwyer Magnehelic Pressure Gauge. Excellent chamber
distribution for EGBE vapors has been demonstrated.
The coefficient of variation of concentrations measured
at eight locations in the chamber in the breathing zones
of the animals was 1%.
Airflow in each chamber was approximately 1000
L/min (14 air changes per hour) with a tgg (theoretically
derived time required for the chamber to reach 99% of
the equilibrium concentration) ofapproximately 20 min.
The chambers were illuminated with artificial room
light. Temperature (Markson Science, Inc., Model
#13177) and relative humidity (Airguide Instrument
Company) gauges were placed inside each chamber
during exposures. Chamber temperature, relative
humidity, and airflow rate were recorded at least four
times during each 6-hr exposure.
Within each chamber, the animal cages were rotated
daily to compensate for any possible, but undetected,
variation in chamber exposure conditions (i.e., con-
centration, temperature, relative humidity).
Target concentrations were 0, 25, 50, 100 and 200
ppm. These exposure concentrations were based on a
range-finding study in pregnant rats and rabbits which
employed concentrations of 450, 200, 75 or 0 ppm, and
an initial rat teratology study with concentrations of
300, 200, 100 and 0 ppm. Maternalmortality was seen at
450 ppm (100% in both species) and maternal toxicity
was seen at all exposure concentrations employed
(except at 75 ppm forrabbits) inthe two studies. Since a
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no-observable effect level (NOEL) could not be ascer-
tained from these studies, the current exposure concen-
trations were selected for both rats and rabbits in the
present study.
Rats
Virgin male and female Fischer 344 rats [NIH:(F-
344)/HlaBR(F141 +3)] (100 days old upon arrival) were
purchased from Hilltop Lab Animals, Inc., Scottdale,
PA. They were quarantined for 2 weeks during which
time representative animals were subjected to fecal
sampling, aerobic bacteriologic cultures of lung tissue,
histologic examination of selected organs and to serum
viralantibody examination forsialodacryoadenitis. Rats
were housed in stainless steel wire-mesh cages with
food (Certified Ground Rodent Chow, Ralston Purina
Co., Richmond, IN) and water (Municipal Authority of
Westmoreland County, Greensburg, PA) available ad
libitum except during exposures. Deotized Animal
Cage Board (Shepherd Specialty Papers, Inc., Kala-
mazoo, MI) was placed beneath the cages and changed
daily. Animals were kept on a 12-hr photoperiod and
room temperatures and humidity were recorded con-
tinuously (Cole-Parmer Hygrothermograph Seven-Day
Continuous Recorder, Model #8368-00, Cole Parmer
Instrument Co., Chicago, IL).
Rats were mated 1:1 (one male:one female) in stain-
less steel wire-mesh cages and the paperboard beneath
the cages was checked twice daily for dropped copula-
tion plugs. Successfully mated (plug-positive) females
were housed singly for the duration of the study. The
day a copulation plug was found was designated gesta-
tional day (gd) 0. Thirty-six plug-positive females were
randomly assigned to each experimental group.
For exposures, plug-positive females were trans-
ferred, one per cage, to stainless steel wire-mesh cages
and the cage carriers, with stainless steel shelves
beneath each row of cages, were moved into the
chambers. Food and water were withheld during
exposures. Exposures were for 6 hr/day, gd 6 through
15. After each exposure, animals were returned to their
original cages. The animals were observed daily for
clinical signs throughout the study (gd 0 through 21).
Food and water consumption was measured for the
intervals gd 0-3, 3-6, 6-9, 9-12, 12-15, 15-18, and
18-21. Maternal body weights were taken on gd 0, 6, 9,
12, 15 and 21.
At scheduled sacrifice on gd 21, rats were anesthe-
tized by carbon dioxide inhalation for collection ofblood
samples. Following blood collections, animals were
sacrificed by carbon dioxide asphyxiation.
Rabbits
Virgin New Zealand White rabbits (3.0 to 3.5 kg,
approximately 5 to 5.5 months old) were purchased
from Hazleton Dutchland Laboratories, Inc., Denver,
PA. They were quarantined for 2 weeks, during which
they were examined by a veterinarian and fecal samples
taken for detection of intestinal parasites. The rabbits
were individually housed in stainless steel wire-mesh
cages with food (Big Red Rabbit Food, Agway, Inc.,
St. Marys, OH) and water (Municipal Authority of
Westmoreland County, Greensburg, PA) available ad
libitum except during exposures. Paperboard was
placed beneath the cages, and photoperiod, tempera-
ture and relative humidity were monitored.
Rabbits were bred, using in-house breeding colony
males. The date of copulation was designated gd 0.
Twenty-four mated females were randomly assigned to
each experimental group.
For exposures, mated females were transferred to
3tainless steel wire-mesh cages in cage carriers which
were moved into the chambers. Food and water were
withheld during exposures. Exposures were for 6
hr/day, gd 6 through 18, in the same chambers as the
rats. After each exposure, animals were returned to
their original cages. The animals were observed daily
for clinical signs throughout the study (gd 0 through
29). Maternal body weights were taken on gd 0, 6, 9, 12,
15, 18, 21 and 29.
At scheduled sacrifice on gd 29, blood was collected
fromeachdoe aftershewasplacedinarabbitrestrainer.
Following blood collection, rabbits were sacrificed by
cervical dislocation.
Thoracolaparotomy, Maternal and
Fetal Examinations
The maternal body cavities were opened by midline
thoracolaparotomy. The gravid uteri, ovaries (including
corpora lutea), cervices, vagina, and peritoneal and
thoracic cavities were examined grossly. Ovarian cor-
pora lutea of pregnancy were counted. Maternal liver,
kidney, thymus, spleen and uterus weights were deter-
mined. The uteri were immediately ligated at their
cervical end to prevent the expulsion ofconceptuses by
myometrial peristalsis. Uteri were externally examined
for signs of hemorrhage. The ligated uteri were re-
moved from the peritoneal cavity and dissected longitu-
dinally to expose their contents. All live and dead
fetuses, placentae, and resorption sites were noted and
recorded. Uteri from females that appeared nongravid
were placed in a 10% ammonium sulfide solution for
detection of early resorptions (2).
Each rabbit fetus was euthanized immediately upon
removal from the uterus by intraperitoneal injection of
sodiumpentobarbital. All live fetuses were weighed and
sexed. Allfetuseswereexamined forexternalmalforma-
tions including cleft palate. One-half of the fetuses
(selected at random) in each litter were examined
for thoracic and peritoneal visceral abnormalities by
modification ofmethods described by Staples (3). These
fetuses were,decapitated and their heads were fixed in
Bouin's solution for examination of craniofacial struc-
tures by sectioning methods modified from Wilson (4,5)
and van Julsingha and Bennett (6). The remaining
49TYL ET AL.
fetuses in each litter were eviscerated, fixed in ethanol,
and then processed for skeletal staining with Alizarin
Red S (7,8), and examined for skeletal malformations.
Hematologic Analyses
Blood samples for erythrocyte osmotic fragility and
hematologic evaluation were obtained from female rats
via retro-orbital bleeding immediately prior to sacrifice.
Approximately 700 ,uL of blood was collected into B-D
Microtainer Brand capillarywhole bloodcollectiontubes
containing sodium heparin as anticoagulant (Becton-
Dickinson Co., Rutherford, NJ) forthe osmotic fragility
assay. Approximately 200 ,uL of blood was collected
into B-D Microtainer Brand Capillary whole blood
collection tubes with EDTA as anticoagulant (Becton-
Dickinson Company, Rutherford, NJ) for hematologic
determinations.
Blood samples for erythrocyte osmotic and hema-
tologic evaluation were obtained from rabbit does
via cardiac puncture immediately prior to sacrifice.
Approximately 2.0 mL ofblood was collected into tubes
with sodiumheparin as anticoagulant (Vacutainer Brand,
Becton-Dickinson Company, Rutherford, NJ) for the
osmotic fragility assay. Approximately 2.0 mL of blood
was collected into tubes containing EDTA as anti-
coagulant (Vacutainer Brand, Becton-Dickinson Com-
pany, Rutherford, NJ) for hematologic determinations.
A 20 pL portion of blood from each female rat and
rabbit was added to each of ten Unopette Reservoirs
(Becton-Dickinson Co., Rutherford, NJ) containing a
specific concentration of buffered saline. Each saline
solution containing red cells was incubated for 20 min
and was then centrifuged for 5 min at 2000 rpm. The
supernatant of each sample was decanted and the
percentage of hemolysis was read using a Trace III
ClinicalChemistrySystem(Beckman Instruments, Inc.,
Fullerton, CA). A precision check of the Trace III
System was performed immediately prior to sample
analysis.
The following hematologic parameters were mea-
sured on all rat and rabbit samples: erythrocyte count,
hemoglobin, and hematocrit. These analyses were per-
formed on a Coulter Counter Model S-Plus IV (Coulter
Electronics, Inc., Hialeah, FL). Commercially available
quality control samples (4C Plus II Coulter Counter
Cell Control, Coulter Diagnostics, Hialeah, FL) were
run prior to the rat and rabbit samples. Mean cor-
puscular volume (MCV), mean corpuscular hemoglo-
bin(MCH) and meancorpuscularhemoglobin concentra-
tions (MCHC) were calculated from the measured
hematologic values.
Statistical Analyses
The unit of comparison was the pregnant female (9).
Results of the quantitative continuous variables (e.g.,
maternal body weights, liver weights) were inter-
compared for the four exposure groups and a control
group by use of Levene's test for equal variances (10),
analysis of variance (ANOVA), and t-tests with
Bonferroni probabilities. The t-tests were used when
the F value from the ANOVA was significant. When
Levene's test indicated homogeneous variances and the
ANOVA was significant, the pooled t-test was used for
pairwise comparisons. When Levene's test indicated
heterogeneous variances, all groups were compared by
an ANOVA for unequal variances (11) followed, when
necessary, by the separate variance t-test.
Nonparametric data obtained following laparohys-
terectomy were statistically treated by using the
Kruskal-Wallis test (12) followed by the Mann-Whitney
ai test (12) when appropriate. Incidence data were
compared by using Fisher's exact test (12). For all
statistical tests, the fiducial limit of 0.05 (two-tailed)
was used as the criterion for significance.
Results
Generation of Atmospheres
and Chamber Parameters
The means of the daily means for EGBE chamber
concentration, temperature and humidity are presented
in Table 1. All EGBE analyses were within + 10% ofthe
Table 1. Summary of chamber concentrations and exposure conditions.
Ethylene glycol monobutyl ether (EGBE) target concentrations
200 ppm 100 ppm 50 ppm 25 ppm 0 ppm
Analytical concn, ppm 201 ± 6a 98 ± 2 50 ± 1 25 ± 1 < MDLb
A/T ratioc 1.005 0.98 1.00 1.00
Nominal conen, ppm 220 110 49 26
A/N ratiod 0.92 0.89 1.01 0.94
Temperature, °F 79.3 ± 1.4a 78.9 ± 2.0 78.9 ± 2.0 79.0 ± 1.8 77.9 ± 2.2
Relative humidity, % 41.2 ± 6.3a 41.4 ± 5.6 40.0 ± 5.8 40.7 ± 6.8 42.8 ± 6.2
aGrand mean of daily means ± SD.
b< MDL = below minimum detection limit of 2 ppm.
cAnalytical/target concentration ratio.
dAnalytical/nominal concentration ratio.
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target concentrations. Since generation of the EGBE
atmosphere required evaporation under heat which
elevated the temperature in the EGBE-exposure
chambers, the control chamber temperature was also
elevated to keep the temperature conditions consistent
in all groups (78-79°F). Relative humidity was main-
tained at 40 to 43%.
Rats
The distribution and fate of all plug-positive rats on
study are presented in Table 2. A small number (five or
six) ofrats in each treatment group were inadvertently
exposed to EGBE for one additional day (gd 16). They
were subsequently removed from study but all their
in-life, necropsy and fetal evaluation data were recorded
and retained in the Bushy Run Research Center
Archives. (For discussion of the results from these
animals, please see the Addendum to this paper.)
Pregnancy rate, as determined at scheduled sacrifice,
was equivalent across all groups. There was a significant
increase in the number oftotally resorbed litters at 200
ppm relative to controls.
Clinical signs observed in a dose-related incidence in
dams during the exposure period (Table 3) included
evidence of hematuria (or hemoglobinuria) especially
early in the exposure period, pale and cold extremities
and necrosis of the tail tip.
Maternal toxicity was also expressed as significant
reductions in body weight during the exposure period
(gd 9, 12, 15) and at sacrifice at 200 ppm, as significantly
reduced weight gain during the exposure period (gd
6-9, 6-12, and 6-15) at 100 and 200 ppm and for the gd
6-21 period for dams exposed to 200 ppm (Table 4).
Food consumption, expressed as grams/dam/day, was
statistically reduced during the exposure period (gd
6-9, 9-12 and 6-15) for dams exposed to 100 and 200
Table 2. Distribution and fate of F-344 rats exposed to EGBE by inhalation on gestational days 6 through 15.
EGBE target concentrations
200 ppm 100 ppm 50 ppm 25 ppm 0 ppm
No. in study 36 36 36 36 36
No. removeda 6 6 5 5 5
No. early deliveries 0 0 0 0 1
No. dead 0 0 0 0 0
No. nonpregnant at
sacrifice 5 7 9 9 7
No. (%) pregnant at
sacrifice 25 (83.3) 23 (76.7) 22 (71.0) 22 (71.0) 23 (76.7)
No. litters totally
resorbed gbt 0 ic 0 0
No. litters examined 16 23 21 22 23
aThese animals were removed because they were inadvertently exposed for one additional day (gestational day 16).
bNine dams had only resorption sites at scheduled sacrifice, seven of which were found only after ammonium sulfide staining.
cOne dam had only resorption sites at scheduled sacrifice, detected after ammonium sulfide staining.
tp < 0.01 versus controls, Fisher's exact test.
Table 3. Clinical observations in Fischer 344 dams exposed to EGBE by inhalation on gestational days 6 through 15.a
EGBE concentrations
0 ppm 25 ppm 50 ppm 100 ppm 200 ppm
Urogenital area stained
red, red black 0 0 0 + + +
Urogenital wetness + + + + + ++
Fur stained (red) + + + + + +
Urogenital encrustation + + + + + ++
Fluid on tray (positive
for occult blood) 0 0 0 + + +
Red fluid on tray 0 0 0 + + +
Periocular wetness 0 + + + + + ++
Perinasal encrustation + + + + + + ++
Extremities cold 0 0 0 0 + +
Extremities pale 0 0 0 0 + ++
Tail tip discolored 0 0 0 0 + +
Tail tip ulcerated 0 0 0 0 + +
Tail tip missing 0 0 0 0 + +
aCode: + + + = majority of dams (75% or more) exhibited the clinical sign sometime during the exposure period; + + = approximately
50% of the dams (30-70%) exhibited the clinical sign sometime during the exposure period; + = up to 25% of the dams exhibited the clinical
sign sometime during the exposure period; 0 = no dams exhibited the clinical sign during the exposure period.
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TIble 4. Maternal weights and weight gain of F-344 rats exposed to EGBE by inhalation.
EGBE target exposure concentrations, gestational days (gd) 6-15
200 ppm 100 ppm 50 ppm 25 ppm 0 ppm
Maternal body weight, g
gd 0 194.7 ± 5.3a 195.6 ± 7.3 195.5 ± 7.2 195.7 ± 7.3 191.8 ± 6.1
gd 6 207.3 ± 5.6 207.1 ± 7.1 206.1 ± 7.8 206.5 ± 7.0 205.2 ± 6.7
gd 9 181.9 ± 6.5* 204.3 ± 10.5 208.4 ± 8.7 210.2 ± 7.5 207.8 ± 7.9
gd 12 191.3 ± 9.1 216.8 ± 8.1 219.0 ± 7.2 218.1 ± 15.0 218.7 ± 8.5
gd 15 203.5 ± 18.0 224.8 ± 13.1 226.7 ± 10.0 230.6 ± 11.3 230.1 ± 9.1
gd 21 244.5 ± 30.91 277.1 ± 19.0 272.4 ± 20.2 277.6 ± 19.5 275.6 + 17.8
Corrected body
weightb 210.4 ± 13.9 215.1 ± 11.0 215.5 ± 7.9 214.5 ± 11.8 215.7 ± 8.3
Maternal body weight gain, g
gd 0-6 12.6 ± 4.1 11.5 ± 2.9 10.6 ± 5.4 10.8 ± 4.0 13.4 ± 3.6
gd 6-9 - 25.4 ± 3.7* - 2.9 ± 6.5* 2.3 ± 4.0 3.7 ± 2.9 2.6 ± 4.2
gd 6-12 - 16.0 ± 6.8* 9.7 ± 2.8t 12.9 ± 3.7 11.6 ± 12.1 13.5 ± 4.5
gd 6-15 - 3.8 ± 17.1* 17.7 ± 9.2* 20.6 ± 7.9 24.1 ± 8.0 24.9 ± 6.0
gd 6-21 37.2 ± 30.0* 70.0 ± 15.8 66.3 ± 19.5 71.1 ± 16.1 70.4 ± 15.3
gd 15-21 41.0 ± 19.7 52.3 ± 14.6 45.7 ± 15.6 47.0 ± 11.5 45.5 ± 10.4
aValues represent mean ± standard deviation; units are in grams.
bCorrected body weight = body weight on gestational day 21 minus gravid uterine weight.
*p < 0.05 compared to control (p = 0.0033 Bonferroni t-test, adjusted).
tp < 0.01 compared to control.
tp < 0.001 compared to control.
Table 5. Food consumption of F-344 rats exposed to EGBE by inhalation.
EGBE target exposure concentrations, gestational days (gd) 6-15
200 ppm 100 ppm 50 ppm 25 ppm 0 ppm
Food consumption,
g/dam/day
gd 0-3 12.0 ± 1.3a 11.6 ± 1.9 11.4 ± 2.4 11.6 ± 1.7 12.6 ± 1.7
gd 3-6 12.8 ± 1.0 12.8 ± 1.2 12.2 ± 1.9 12.8 ± 1.0 13.3 ± 1.5
gd 6-9 2.9 ± 1.0* 10.9 ± 1.7* 13.7 ± 1.4 14.0 ± 0.9 14.4 ± 1.0
gd 9-12 9.4 + 2.41 15.0 ± 1.2* 15.4 ± 1.2 15.3 ± 3.2 16.0 ± 1.4
gd 12-15 14.9 ± 3.4 15.1 ± 2.4 15.6 ± 3.3 16.0 ± 2.0 16.7 ± 1.2
gd 15-18 19.0 ± 2.5 18.6 ± 1.7 17.4 ± 2.0 18.3 ± 3.3 19.1 ± 2.9
gd 18-21 19.7 ± 2.2 19.2 ± 1.9 17.9 ± 2.8 18.2 ± 1.1 18.6 ± 1.4
gd 0-6
(prior to treatment) 12.4 ± 0.9 12.2 ± 1.3 11.8 ± 1.8 12.2 ± 1.1 12.9 ± 1.5
gd 6-15
(during treatment) 9.0 ± 2.0$ 13.7 ± 1.3* 14.9 ± 1.6 15.1 ± 1.7 15.7 ± 0.9
gd 15-21
(following
treatment) 19.4 ± 2.2 18.9 ± 1.6 17.6 ± 2.0 18.2 ± 2.0 18.9 ± 1.9
aValues represent mean ± standard deviation; units are in grams per dam per day.
*p < 0.05 compared to control.
tp < 0.001 compared to control.
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Table 6. Water consumption of F-344 rats exposed to EGBE by inhalation.
EGBE target exposure concentrations, gestational days (gd) 6-15
200 ppm 100 ppm 50 ppm 25 ppm 0 ppm
Water consumption,
g/dam/day
gd 0-3 16.9 ± 2.9(25)a 17.4 ± 3.3(23) 15.8 ± 4.4(21) 16.6 ± 2.0(21) 17.7 ± 2.1(22)
gd 3-6 17.3 ± 2.0(25) 18.4 ± 2.4(23) 17.6 ± 2.5(21) 17.3 ± 2.5(21) 17.3 ± 1.9(22)
gd 6-9 6.4 ± 2.7(25)* 18.1 ± 5.6(23) 17.9 ± 2.6(22) 18.2 ± 1.6(22) 19.1 ± 2.7(22)
gd 9-12 20.1 ± 5.1(23) 25.3 ± 7.2(23) 21.9 ± 2.9(22) 22.1 ± 4.9(21) 22.0 ± 2.8(23)
gd 12-15 30.1 ± 5.9(23)* 27.1 ± 7.3(23) 23.7 ± 5.3(22) 24.6 ± 4.4(21) 25.5 ± 2.9(23)
gd 15-18 31.5 ± 6.5(25) 33.7 ± 3.4(22) 30.3 ± 4.8(22) 28.7 ± 6.4(22) 31.4 ± 4.0(23)
gd 18-21 31.2 ± 7.7(21) 33.3 ± 3.4(21)b* 30.0 ± 5.3(22) 29.7 ± 2.5(21) 30.4 ± 3.7(23)
gd 0-6 (prior to
treatment) 17.1 ± 2.0(25) 17.9 ± 2.4(23) 16.6 ± 2.4(20) 16.8 ± 1.6(21) 17.6 ± 1.9(21)
gd 6-15 (during
treatment) 19.1 ± 3.8(21)t 23.5 ± 4.0(23) 21.2 ± 2.8(22) 21.8 ± 1.9(20) 22.2 ± 2.2(23)
gd 15-21 (following
treatment) 31.6 ± 6.9(21) 33.6 ± 3.1(21)* 30.1 ± 4.8(22) 29.1 ± 3.5(21) 30.9 ± 3.6(23)
aValues represent mean standard deviation; units are in grams per dam per day; values in parentheses indicate N for each group. Reduced
N values were due to spillage.
bThe statistical significance for this value was assessed using the Welch ANOVA test statistic. This value was not statistically significant
when the Brown-Forsythe test (ANOVA) was employed.
*p < 0.05 compared to control.
tp < 0.01 compared to control.
tp < 0.001 compared to control.
Table 7. Hematologic determinations for Fischer 344 rat dams exposed to EGBE by inhalation on gestation days (gd) 6-15.a
Target Hemolysis, % Hematologic parametersb
concentration, 0.55% 0.50% 0.45% RBC Hgb, Hct,
ppm saline saline saline x 10-/mm3 g/dL %
200 8.2 39.5 82.4 5.83* 13.8$ 42.0*
(7.1) (14.2) (11.2) (0.60) (1.4) (4.8)
100 4.9 33.5 76.8 5.77* 11.9 35.2
(5.1) (10.4) (8.8) (0.47) (0.9) (2.9)
50 7.3 38.4 77.0 6.36 12.0 35.0
(7.5) (12.7) (10.3) (0.55) (1.0) (3.0)
25 5.1 32.4 74.4 6.37 12.0 35.0
(5.4) (9.2) (7.2) (0.34) (0.6) (1.9)
0 8.3 38.0 77.7 6.36 12.1 35.1
(6.7) (12.1) (6.5) (0.41) (0.8) (2.3)
aData are presented as mean (standard deviation).
bRBC = red blood cells (x 106/mm3); Hgb = hemoglobin (g/dL); Hct = hematocrit (%).
tp < 0.001 versus controls.
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ppm (Table 5). Water consumption, expressed as
grams/dam/day, was also significantly reduced for the
periods gd 6-9, 12-15 and 6-15 for dams at 200 ppm.
Water consumption was elevated relative to controls for
dams exposed to 100 ppm during the postexposure
periods gd 18-21 and 15-21 (Table 6).
Hematologic determinations on dams at scheduled
sacrifice (Tables 7 and 8) indicated no alterations in
osmotic fragility of erythrocytes but significant reduc-
tions in erythrocyte (RBC) count, and significant in-
creases in hemoglobin and hematocrit (packed red
blood cell volume) at 200 ppm. RBC count was also
Table 8. Erythrocyte indices for Fischer 344 rat dams exposed to
EGBE by inhalation on gestation days 6-15.
Erythrocyte indicesa
Target MCV, MCH, MCHC,
concentration, ppm j±m3b pgc g/dLc
200 71.41 23.6k 32.8k
[1.2] (0.8) (0.8)
100 60.81 21.0 33.8t
[0.9] (2.0) (0.7)
50 55.0 19.0 34.4
[0.2] (0.4) (0.6)
25 54.9 18.9 34.5
[0.5] (0.3) (0.6)
0 55.0 18.9 34.4
[0.6] (0.3) (0.6)
'MCV = mean corpuscular volume (Rm3), MCH = mean corpus-
cular hemoglobin (pg), MCHC = mean corpuscular hemoglobin
concentration (g/dL).
bMedian [quartile deviation].
CMean (standard deviation).
"O.01 - p 2 0.001 versus controls.
tp < 0.001 versus controls.
reduced at 100 ppm. The size of the red blood cell
(MCV) was significantly enlarged at 200 and 100 ppm,
and the hemoglobin per cell (MCH) was significantly
increased. The meancorpuscularhemoglobin concentra-
tion (MCHC) was significantly increased. The mean
corpuscular hemoglobin concentration (MCHC) was
significantly reduced at 100 and 200 ppm relative to
controls.
Atscheduled sacrifice, maternalgraviduterineweight
was significantly reduced, and absolute and relative
spleen weight and relative kidney weight were elevated
compared to controls at 200 ppm (Table 9).
Reproductive toxicity was also evident at 200 ppm
(Table 10). The number of viable implants and the
percent live fetuses per litter were reduced relative to
controls and the number ofnonviable implants, primar-
ily due to the elevated number of early embryonic
resorptions, waselevated at200 ppmrelativetocontrols.
Preimplantation loss was also elevated, but the differ-
ence was not statistically significant. Sex ratio (%
males) and the body weight of male or female fetuses
per litter were unaffected by treatment (Table 10).
The results of fetal evaluations are presented in
Tables 11 and 12. There were no statistically significant
increases in the incidence ofexternal, visceral, skeletal
or total malformations due to treatment (Table 11). The
incidence of variations observed in rat fetuses in the
present study is presented in Table 12. Evidence for
retarded skeletal ossification was seen at 100 and 200
ppm. At 200 ppm, there was a significant increase in the
number of litters with one or more fetuses exhibiting
unossified skeletal elements, e.g., the anterior arch of
the atlas, cervical centra 5 and 6, and poorly ossified
skeletal elements, e.g., cervical arches, sternebrae 1, 3,
4 and 6 and proximal phalanges in the forelimbs. At 100
ppm, there was a significant increase in the incidence of
Table 9. Maternal organ weights of F-344 rats exposed to EGBE by inhalation.
EGBE target exposure concentrations, gestational days (gd) 6-15a
200 ppm 100 ppm 50 ppm 25 ppm 0 ppm
Maternal body weight
(gd 21), g 244.5 ± 30.9 277.1 ± 19.0 272.4 ± 20.2 277.6 ± 19.5 275.6 ± 17.8
Organ weights, g
Uterus 34.09 ± 28.62t 62.04 ± 17.91 56.94 ± 20.44 63.10 ± 11.76 59.90 ± 17.56
Liver 10.42 ± 2.09 11.30 ± 1.04 10.67 ± 1.06 11.19 ± 1.22 11.17 ± 0.88
Relative liver, %b 4.95 ± 0.97 5.25 ± 0.39 4.96 ± 0.48 5.20 ± 0.41 5.18 ± 0.38
Thymus 0.25 ± 0.10 0.26 ± 0.06 0.25 ± 0.08 0.27 ± 0.08 0.26 ± 0.07
Relative thymus, %b 0.12 ± 0.04 0.12 ± 0.03 0.12 ± 0.03 0.12 ± 0.04 0.12 ± 0.03
Spleen 0.65 ± 0.09* 0.57 ± 0.06 0.60 ± 0.26 0.53 ± 0.07 0.54 ± 0.05
Relative spleen %b 0.31 ± 0.04k 0.27 ± 0.03 0.28 ± 0.12 0.25 ± 0.03 0.25 ± 0.02
Kidney 1.54 ± 0.17 1.44 ± 0.08 1.39 ± 0.10 1.42 ± 0.10 1.46 ± 0.14
Relative kidney, %b 0.74 ± 0.09* 0.68 ± 0.04 0.65 ± 0.04 0.66 ± 0.05 0.68 ± 0.05
aValues represent mean ± standard deviation.
bRelative organ weight = organ weight expressed as a percent of corrected body weight.
*p < 0.05 as compared to control.
tp < 0.01 as compared to control.
tp < 0.001 as compared to control.
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Table 10. Reproductive toxicity evaluation of F-344 rats exposed to EGBE by inhalation.
EGBE target exposure concentrations, gestational days (gd) 6-15a
200 ppm 100 ppm 50 ppm 25 ppm 0 ppm
Corpora lutea 15.7 ± 5.4 13.2 ± 1.2 13.2 ± 5.3 13.0 ± 1.7 12.9 ± 1.8
Total implants 8.7 ± 3.8 10.3 ± 3.2 9.1 ± 3.6 10.3 ± 2.2 10.0 ± 3.5
Viable implants 4.7 ± 4.5k 9.9 ± 3.3 8.9 ± 3.7 10.0 ± 2.2 9.4 ± 3.2
Nonviable implants 4.0 ± 4.6t 0.4 ± 1.1 0.2 ± 0.4 0.3 ± 0.5 0.5 ± 0.7
Embryonic resorptions 2.8 ± 4.7bt 0.0 ± 0.0 0.1 ± 0.3c 0.0 ± 0.0 0.0 ± 0.0
Embryonic resorptions
with placenta 1.2 ± 2.2 0.3 ± 0.9 0.1 ± 0.4 0.2 ± 0.4 0.4 ± 0.7
Dead and macerated
fetuses 0.0 ± 0.2 0.1 ± 0.3 0.0 ± 0.0 0.0 ± 0.2 0.1 ± 0.3
Live fetuses, % 52.7 ± 45.1t 94.4 ± 12.9 93.3 ± 21.4 97.5 ± 4.3 95.7 ± 5.9
Preimplantation loss, % 39.7 ± 30.6 22.2 ± 22.7 25.2 ± 29.2 19.6 ± 18.0 23.7 ± 26.2
Sex ratio 43.8 ± 17.2 51.8 ± 20.0 51.2 ± 15.9 50.6 ± 19.8 50.5 ± 23.2
Mean litter weight, g
Male fetus weight 4.4 ± 0.4 4.5 ± 0.2 4.6 ± 0.4 4.5 ± 0.ld 4.5 ± 0.2
Female fetus weight 4.0 ± 0.5 4.2 ± 0.2 4.3 ± 0.4 4.2 ± 0.2 4.3 ± 0.2e
aValues represent mean ± standard deviation on a per litter basis.
bNine of twenty-five dams had embryonic resorptions, seven of which were found to be gravid by ammonium sulfide staining only.
cOne of twenty-two dams had embryonic resorptions, detected only by ammonium sulfide staining.
dN = 22, 20, 21, and 22 for exposure groups 100, 50, 25 and 0 ppm, respectively. One litter from each group had only female fetuses.
eN = 22; one litter had only male fetuses.
tp < 0.01 versus controls.
tp < 0.001 versus controls.
Table 11. Malformations observed in Fischer 344 rat fetuses exposed to EGBE in utero.a
Fetusesb Littersc
0 ppm 25 ppm 50 ppm 100 ppm 200 ppm 0 ppm 25 ppm 50 ppm 100 ppni 200 ppm
EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE
Number exanmined
externallyd
Umbilical hernia
No.
Number examined
viscerallye
Right aortic arch
No.
Ventricular septal
defect
No.
Situs inversus
No.
Left carotid artery
emerges from arch
on right
No.
Dorsal deflected
aortic arch
No.
Retroesophageal
aortic arch
No.
Microphthalmia,
right
No.
217 221 196 228 117 23 22 21 23
0 1 1 0 0 0 1 1 0
(0.0) (0.5) (0.5) (0.0) (0.0) (0.0) (4.5) (4.8) (0.0)
112 115 104 119 64 23 22 21 23
0 0 0 0 1 0 0 0 0
(0.0) (0.0) (0.0) (0.0) (1.6) (0.0) (0.0) (0.0) (0.0)
16
0
(0.0)
16
1
(6.2)
0 1 0 0 1 0 1 0 0. 1
(0.0) (0.9) (0.0) (0.0) (1.6) (0.0) (4.5) (0.0) (0.0) (6.2)
0 0 0 0 1 0 0 0 0 1
(0.0) (0.0) (0.0) (0.0) (1.6) (0.0) (0.0) (0.0) (0.0) (6.2)
0 0 1 0 0 0 0 1 0 0
(0.0) (0.0) (1.0) (0.0) (0.0) (0.0) (0.0) (4.8) (0.0) (0.0)
0 0 0 0 1 0 0 0 0
(0.0) (0.0) (0.0) (0.0) (1.6) (0.0) (0.0) (0.0) (0.0)
1
(6.2)
0 0 1 0 0 0 0 1 0 0
(0.0) (0.0) (1.0) (0.0) (0.0) (0.0) (0.0) (4.8) (0.0) (0.0)
1 0 0 1 1 1 0 0 1 1
(0.9) (0.0) (0.0) (0.8) (1.6) (4.3) (0.0) (0.0) (4.3) (6.2)
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Table 11. (continued)
Fetuses' Littersc
0 ppm 25 ppm 50 ppm 100 ppm 200 ppm 0 ppm 25 ppm 50 ppm 100 ppm 200 ppm
EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE
Microphthalmia,
left
No.
Incomplete
septation of aorta
and pulmonary
artery
No.
0 0 1 1 0
(0.0) (0.0) (1.0) (0.8) (0.0)
0 0 0 0 1
(0.0) (0.0) (0.0) (0.0) (1.6)
0 0 1 1 0
(0.0) (0.0) (4.8) (4.3) (0.0)
0 0 0 0 1
(0.0) (0.0) (0.0) (0.0) (6.2)
Number examined
skeletally'
Thoracic vertebrae
curved
No.
Unossified rib,
unilateral
No.
Sternebrae
misshapen
No.
Digit, curved and
abnormal size
No.
Tympanic annuli
abnormal
No.
Microagnathia
No.
Total malformations
Externald
No.
Viscerale
No.
Skeletalf
No.
Total
No.
105 106 92 109 49 23 22 209 229 15h
0 1 0 0 0
(0.0) (0.9) (0.0) (0.0) (0.0)
0 0 0 0 1
(0.0) (0.0) (0.0) (0.0) (2.0)
0 1 0 0 0
(0.0) (0.9) (0.0) (0.0) (0.0)
0 1 0 0 0
(0.0) (0.9) (0.0) (0.0) (0.0)
0 1 0 0 0
(0.0) (0.9) (0.0) (0.0) (0.0)
0 1 0 0 0
(0.0) (0.9) (0.0) (0.0) (0.0)
0 1 1 0 0
(0.0) (0.5) (0.5) (0.0) (0.0)
1 1 2 2 3
(0.9) (0.9) (1.9) (1.7) (4.7)
0 3 0 0 1
(0.0) (2.8) (0.0) (0.0) (2.0)
1 5 3 2 4
(0.5) (2.3) (1.5) (0.9) (3.4)
0 1 0 0 0
(0.0) (4.5) (0.0) (0.0) (0.0)
0 0 0 0 1
(0.0) (0.0) (0.0) (0.0) (6.7)
0 1 0 0 0
(0.0) (4.5) (0.0) (0.0) (0.0)
0 1 0 0 0
(0.0) (4.5) (0.0) (0.0) (0.0)
0 1 0 0 0
(0.0) (4.5) (0.0) (0.0) (0.0)
0 1 0 0 0
(0.0) (4.5) (0.0) (0.0) (0.0)
0 1 1 0 0
(0.0) (4.5) (4.8) (0.0) (0.0)
1 1 2 2 3
(4.3) (4.5) (9.5) (8.7) (18.7)
0 3 0 0 1
(0.0) (13.6) (0.0) (0.0) (6.7)
1 5 2 2 4
(4.3) (22.7) (9.5) (8.7) (25.0)
'A single fetus may be represented more than once in listing individual defects.
bOnly live fetuses were examined for malformations.
CIncludes litters with one or more malformed fetuses.
dAll fetuses were examined externally.
eApproximately 50% of each litter were examined viscerally (3) and for soft tissue craniofacial malformations (4).
fApproximately 50% of each litter were examined for skeletal malformations after staining with Alizarin Red S. NOne litter contained only one live fetus. By convention this fetus was subjected to visceral and craniofacial examination.
hThe skeletal preparations from one litter were macerated and could not be evaluated.
unossified cervical centrum 6. At 100 and 200 ppm, At 200 ppm there was also a decreased incidence of
there was a decreased incidence of bilobed cervical bilobed thoracic centra 9 and 13 and of poorly ossified
centrum 5 (primarily because at these exposure concen- proximal phalanges ofthe hindlimb relative to controls.
trations this skeletal element was largely unossified). Rudimentary rib and/or bone island at the first lumbar
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Table 12. Variations observed in Fischer 344 rat fetuses exposed to EGBE in utero.a
Fetusesb
0 ppm 25 ppm 50 ppm 100 ppm 200 ppm
EGBE EGBE EGBE EGBE EGBE
Number examined
externallyc
Ecchymoses, trunk
No.
Ecehymoses, head
No.
Ecchymoses, extremitie
No.
Number examined
viscerally'
Thymus, hemorrhagic
No.
Shortened innominate a
No.
217 221
21 22
(9.7) (10.0)
5 3
(2.3) (1.4)
4 5
(1.8) (2.3)
112 115
3 6
(2.7) (5.2)
rtery
0 2
(0.0) (1.7)
Missing innominate artery
No. 0
% (0.0)
White nodule, caudate lobe of liver
No. 1
% (0.9)
Liver discoloration
No. 0
% (0.0)
Liver hemorrhagic
No. 0
% (0.0)
Red foci, right kidney
No. 1
% (0.9)
Red foci, both kidneys
No. 0
% (0.0)
Dark red coagulation in abdominal
No. 0
% (0.0)
Lungs hemorrhagic
No. 0
% (0.0)
Fetal atelectasis
0
(0.0)
2
(1.7)
1
(0.9)
0
(0.0)
2
(1.7)
0
(0.0)
cavity
0
(0.0)
0
(0.0)
No. 2 4
% (1.8) (3.5)
Fourth cusp on aortic semilunar valve
No. 1 0
% (0.9) (0.0)
Red foci on right atrium
No. 0 0
% (0.0) (0.0)
Lateral ventricles dilated (cerebrum)
No. 2 1
% (1.8) (0.9)
Third ventricles dilated (diencephalon)
No. 1 0
% (0.9) (0.0)
Enlarged fourth ventricle (cerebellum)
No. 21 14
% (18.7) (12.2)
Nasal septum or passage distorted
No. 2 8
% (1.8) (7.0)
196
27
(13.8)
3
(1.5)
5
(2.6)
104
6
(5.8)
2
(1.9)
0
(0.0)
2
(1.9)
1
(1.0)
1
(1.0)
0
(0.0)
1
(1.0)
1
(1.0)
1
(1.0)
3
(2.9)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
19
(18.3)
8
(7.7)
228
29
(12.7)
3
(1.3)
8
(3.5)
119
6
(5.0)
0
(0.0)
0
(0.0)
2
(1.7)
0
(0.0)
0
(0.0)
2
(1.7)
0
(0.0)
0
(0.0)
0
(0.0)
2
(1.7)
0
(0.0)
1
(0.8)
1
(0.8)
0
(0.0)
14
(11.8)
7
(5.9)
117
16
(13.8)
4
(3.4)
4
(3.4)
64
4
(6.2)
2
(3.1)
1
(1.6)
2
(3.1)
0
(0.0)
0
(0.0)
1
(1.6)
0
(0.0)
0
(0.0)
0
(0.0)
8
(12.5)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
8
(12.5)
1
(1.6)
Littersc
0 ppm
EGBE
23
15
(65.2)
4
(17.4)
3
(13.0)
23
3
(13.0)
0
(0.0)
0
(0.0)
1
(4.3)
0
(0.0)
0
(0.0)
1
(4.3)
0
(0.0)
0
(0.0)
0
(0.0)
1
(4.3)
1
(4.3)
0
(0.0)
2
(8.7)
1
(4.3)
13
(56.5)
2
(8.7)
25 ppm
EGBE
22
12
(54.5)
3
(13.6)
5
(22.7)
22
6
(27.3)
2
(9.1)
0
(0.0)
1
(4.5)
1
(4.5)
0
(0.0)
2
(9.1)
0
(0.0)
0
(0.0)
0
(0.0)
2
(9.1)
0
(0.0)
0
(0.0)
1
(4.5)
0
(0.0)
9
(40.9)
5
(22.7)
50 ppm
EGBE
21
12
(57.1)
3
(14.3)
5
(23.8)
21
5
(23.8)
2
(9.5)
0
(0.0)
2
(9.5)
1
(4.8)
1
(4.8)
0
(0.0)
1
(4.8)
1
(4.8)
1
(4.8)
2
(9.5)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
11
(52.4)
5
(23.8)
100 ppm 200 ppm
EGBE EGBE
23 16
16 8
(69.6) (50.0)
3 3
(13.0) (18.7)
5 3
(21.7) (18.7)
23 16
5 4
(21.7) (25.0)
0 2
(0.0) (12.5)
0 1
(0.0) (6.2)
2 1
(8.7) (6.2)
0 0
(0.0) (0.0)
0 0
(0.0) (0.0)
2 2
(8.7) (6.2)
0 0
(0.0) (0.0)
0 0
(0.0) (0.0)
0 0
(0.0) (0.0)
2 4
(8.7) (25.0)
0 0
(0.0) (0.0)
1 0
(4.3) (0.0)
1 0
(4.3) (0.0)
0 0
(0.0) (0.0)
9 7
(39.1) (43.7)
4 1
(17.4) (6.2)
57TYL ET AL.
Table 12. (continued)
Fetusesb Littersc
0 ppm 25 ppm 50 ppm 100 ppm 200 ppm 0 ppm 25 ppm 50 ppm 100 ppm 200 ppm
EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE
Gel-like material between skin and nasal bone
No. 0 0 1
% (0.0) (0.0) (1.0)
Number examined skeletallyf106 106 92
Anterior arch of Atlas, unossified
No. 1 5 2
% (0.9) (4.7) (2.2)
Cervical centra 1-3 and/or 4, poorly ossified
No. 57 73 58
% (53.8) (68.9) (63.0)
Cervical centra #5, unossified
No. 13 17 11
%o (12.3) (16.0) (12.0)
Cervical centra #5, bilobed
No. 19 11 13
% (17.9) (10.4) (14.1)
Cervical centra #6, unossified
No. 2 4 5
% (1.9) (3.8) (5.4)
Cervical centra #6, bilobed
No. 40 33 27
% (37.7) (31.1) (29.3)
Cervical arches 1-6 and/or 7, poorly ossified
No. 2 4 7
% (1.9) (3.8) (7.6)
Throacic centra #1, bilobed
No. 47 30 46
% (44.3) (28.3) (50.0)
Thoracic centra #9, bilobed
No. 15 16 10
% (14.2) (15.1) (10.9)
Thoracic centra #13, bilobed
No. 31 24 22
% (29.2) (22.6) (23.9)
Sternebra #1, poorly ossified
No. 4 12 5
% (3.8) (11.3) (5.4)
Sternebra #3, poorly ossified
No. 4 11 4
% (3.8) (10.4) (4.3)
Sternebra #4, poorly ossified
No. 13 23 14
% (12.3) (21.7) (15.2)
Sternebra #6, poorly ossified
No. 28 24 19
% (26.4) (22.6) (20.7)
Sternebra #5, bilobed
No. 14 34 18
% (13.2) (32.1) (19.6)
Proximal phalanges poorly ossified (hindlimb)
No. 66 53 35
% (62.3) (50.0) (38.0)
Proximal phalanges unossified (forelimb)
No. 12 18 14
% (11.3) (17.0) (15.2)
Rudimentary rib lumbar-1, unilateral
No. 3 5 3
% (2.8) (4.7) (3.3)
Rudimentary rib lumbar-1, bilateral
No. 0 1 2
% (0.0) (0.9) (2.2)
Extra rib, unilateral
No. 0 0 0
% (0.0) (0.0) (0.0)
Bone island at lumbar-1
No. 2 2 5
0 0 0
(0.0) (0.0) (0.0)
109 50 23
3 10 1
(2.8) (20.0) (4.3)
62 9 22
(56.9) (18.0) (95.7)
22 24 9
(20.2) (48.0) (39.1)
6 1 14
(5.5) (2.0) (60.9)
11 12 2
(10.1) (24.0) (8.7)
20 6 19
(18.3) (12.0) (82.6)
2 7 2
(1.8) (14.0) (8.7)
34 22 20
(31.2) (44.0) (87.0)
10 4 11
(9.2) (8.0) (47.8)
17 6 18
(15.6) (12.0) (78.3)
5 12 3
(4.6) (24.0) (13.0)
11 10 3
(10.1) (20.0) (13.0)
25 16 7
(22.9) (32.0) (30.4)
28 35 11
(25.7) (70.0) (47.8)
16 9 9
(14.7) (18.0) (39.1)
56 10 22
(51.4) (20.0) (95.7)
23 21 7
(21.1) (42.0) (30.4)
5 4 3
(4.6) (8.0) (13.0)
1 3 0
(0.9) (6.0) (0.0)
0 2 0
(0.0) (4.0) (0.0)
0
(0.0)
22
4
(18.2)
22
(100.0)
10
(45.5)
9
(40.9)
4
(18.2)
17
(77.3)
4
(18.2)
12*
(54.5)
10
(45.5)
16
(72.7)
8
(36.4)
8
(36.4)
13
(59.1)
14
(63.6)
17*
(77.3)
20
(90.9)
12
(54.5)
5
(22.7)
1
(4.5)
0
(0.0)
1
(4.8)
209
2
(10.0)
20
(100.0)
9
(45.0)
11
(55.0)
4
(20.0)
13
(65.0)
4
(20.0)
18
(90.0)
9
(45.0)
13
(65.0)
3
(15.0)
4
(20.0)
9
(45.0)
12
(60.0)
14
(70.0)
15
(75.0)
8
(40.0)
3
(15.0)
2
(10.0)
0
(0.0)
0
(0.0)
229
2
(9.1)
22
(100.0)
14
(63.6)
4*
(18.2)
10*
(45.5)
13
(59.1)
2
(9.1)
16
(72.7)
7
(31.8)
11
(50.0)
5
(22.7)
6
(27.3)
13
(59.1)
14
(63.6)
11
(50.0)
22
(100.0)
10
(45.5)
4
(18.2)
1
(4.5)
0
(0.0)
0
(0.0)
15h
7*
(46.7)
7*
(46.7)
12*
(80.0)
1*
(6.7)
10l
(66.7)
5*
(33.3)
7*
(46.7)
12
(80.0)
2*
(13.3)
3*
(20.0)
7*
(46.7)
7*
(46.7)
ll*
(73.3)
14*
(93.3)
9
(60.0)
8*
(53.3)
10*
(66.7)
4
(26.7)
3
(20.0)
2
(13.3)
7 4 2 2 5 7 4
(1.9) (1.9) (5.4) (6.4) (8.0) (8.7) (9.1) (25.0) (31.8) (26.7)
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Table 12. (continued)
Fetusesb Littersc
0 ppm 25 ppm 50 ppm 100 ppm 200 ppm 0 ppm 25 ppm 50 ppm 100 ppm 200 ppm
EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE
Rudimentary rib, thoracic area
No. 0 0 0 0 1 0 0 0 0 1
% (0.0) (0.0) (0.0) (0.0) (2.0) (0.0) (0.0) (0.0) (0.0) (6.7)
'A single fetus may be represented more than once in listing individual defects.
bOnly live fetuses were examined for defects.
cIncludes litters with one or more affected fetuses.
dAll fetuses were examined externally eApproximjately 50% of each litter were examined viscerally (3) and for soft tissue craniofacial defects (4).
'Approximately 50% of each litter were examined for skeletal defects after staining with Alizarin Red S. Only those parameters whose
incidence differed significantly from that of controls at p < 0.05, Fisher's exact test (two-tailed) and related parameters are indicated.
90ne litter contained only one live fetus. By convention this fetus was subjected to visceral and craniofacial examination.
hThe skeletal preparations from one litter were macerated and could not be evaluated.
*p < 0.05 versus controls, Fisher's exact test (two-tailed).
Table 13. Distribution and fate of NZW rabbits exposed to EGBE by inhalation on gestational days 6 through 18.
EGBE target concentrations
200 ppm 100 ppm 50 ppm 25 ppm 0 ppm
No. in study 24 24 24 24 24
No. removed 0 0 la 0 0
No. abortions 4b 1 0 0 0
No. dead 4c 0 0 0 0
No. sacrificed
(gd 29) 16 23 23 24 24
No. nonpregnant
at sacrifice 1 3 1 1 4
No. (%) pregnant
at sacrifice 15 (93.8) 20 (87.0) 22 (95.7) 23 (95.8) 20 (83.3)
No. litters
examined 15 19d 22 22e 20
aAnimal removed from study because it died immediately following cardiac puncture; all fetuses were dead when cesarean section was
performed.
bThe number of abortions in this group was not significantly elevated relative to that in controls by Fisher's exact test.
CAll females were confirmed pregnant at postmortem necropsy. The number of deaths was not significantly elevated relative to controls.
dOne rabbit was found gravid at cesarean section with only one embryonic resorption with placenta.
eOne rabbit was found gravid at cesarean section with 10 dead and macerated fetuses only.
Table 14. Clinical observations in NZW rabbit does exposed to EGBE on gestational days 6 through 18.'
EGBE concentration
0 ppm 25 ppm 50 ppm 100 ppm 200 ppm
Deaths
By gd 8 2b
By gd 10 1
Sacrificed in extremis (gd 9) 1
Behavior
Hypoactive 1
Listless 1
Lethargic 1
Alopecia + + + + +
Urogenital area stained + + + + + +
Fur stained + + + + + +
Periocular wetness + + + + + + +
Periocular encrustation + + + + +
Perinasal wetness + + 0 0 + +
Perinasal discharge 0 0 0 0 +
Red fluid on tray or paperboard 0 0 0 + +
Abortion (placental/fetal tissue
on paperboard; gd 21-25) la 4a
aCode: + + = approximately 50% of the does (30-70%) exhibited the clinical sign sometime during the exposure period; + = up to 25%
of the does exhibited the clinical sign sometime during the exposure period; 0 = no does exhibited the clinical sign during the exposure
period.
bNumber of does exhibiting the clinical sign sometime during the exposure or postexposure period.
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Table 15. Maternal weights and weight gain of NZW rabbits exposed to EGBE by inhalation.
EGBE target exposure concentrations, gestational days (gd) 6-15
200 ppm 100 ppm 50 ppm 25 ppm 0 ppm
Maternal body weight, g
gd 0 3892.1 ± 520.6a 3910.5 ± 517.0 3748.3 ± 563.5 4086.6 ± 529.7 4077.8 ± 612.2
gd 6 4047.9 ± 535.2 4071.0 ± 505.8 3958.2 ± 641.5 4249.1 ± 530.3 4242.2 ± 599.1
gd 9 3844.5 ± 449.6b 4007.6 ± 477.7 3877.7 ± 596.9 4190.4 ± 525.7 4164.3 ± 583.9
gd 12 3786.5 ± 393.6c 4009.7 ± 451.1 3889.1 ± 586.5 4195.7 ± 526.0 4196.7 ± 536.5
gd 15 3811.3 ± 406.2c* 4022.7 ± 436.1 3945.0 ± 590.3 4227.7 ± 506.1 4221.8 ± 540.8
gd 21 3878.1 ± 422.2c 4099.0 ± 443.1 4050.6 ± 593.7 4316.9 ± 500.7 4290.9 ± 383.1d
gd 29 3994.4 ± 426.0e 4163.5 ± 445.3' 4047.7 ± 514.9 4314.7 ± 502.7h 4363.1 455.0
Corrected body
weightg 3553.5 ± 380.6 3692.1 ± 413.7 3507.5 ± 456.6 3784.8 474.oh 3795.2 ± 434.0
Maternal body weight gain, g
gd 0-6 155.8 ± 101.4 160.5 ± 72.2 209.9 ± 145.3 162.5 ± 104.7 164.4 ± 126.2
gd 6-9 -134.2 ± 144.1b -63.4 ± 66.5 -80.4 ± 82.3 -58.7 ± 60.4 -77.9 ± 80.8
gd 6-12 -102.6 ± 58.0c -61.3 ± 89.9 -69.1 ± 90.5 -53.4 ± 94.1 -45.6 ± 99.9
gd 6-15 -77.7 ± 70.0c -48.3 ± 119.5 -13.1 ± 113.7 -21.4 ± 133.5 -20.4 ± 129.5
gd 6-21 -11.0 ± 152.3c 28.0 ± 247.9 92.4 ± 146.4 67.8 ± 202.5 74.2 ± 233.4
gd 6-29 85.7 ± 162.7e 66.3 ± 347.3f 89.6 ± 275.7 55.3 ± 199.4h 120.9 ± 246.9
gd 21-29 33.1 ± 123.8e 28.9 ± 204.7f -2.8 ± 190.1 -3.5 135.6h 41.9 ± 177.8d
aValues represent mean ± standard deviation; units are in grams.
bN = 21 - Two rabbits dead prior to gestational day 9.
CN = 19- Four rabbits dead prior to gestational day 12.
dN = 16- Four rabbits were accidentally not weighed.
eN = 15 - Four rabbits dead prior to gestational day 12 and four rabbits aborted prior to gestational day 29.
fN = 20- One rabbit aborted prior to gestational day 29.
gCorrected body weight = body weight on gd 29 minus gravid uterine weight.
hN = 22- One rabbit died immediately following cardiac puncture on gestational day 29; a final body weight was not obtained.
*p < 0.05 versus controls.
Table 16. Hematologic determinations for NZW rabbit does exposed to EGBE by inhalation on gestational days 6-18.'
Target Hemolysis, % Hematologic parametersb
concentration, 0.55% 0.50% 0.45% RBC Hgb, Hct,
ppm saline saline saline x 1076/mm3 g/dL t
200 20.2 54.2 88.1 5.87 13.1 40.6
(14.0) (19.8) (10.7) (0.40) (0.8) (2.7)
100 23.8 56.1 87.3 6.13 13.5t 41.5t
(19.4) (21.4) (12.5) (0.62) (1.2) (4.0)
50 19.2 47.7 81.4 5.94 13.1 40.0
(13.2) (18.8) (14.0) (0.43) (0.9) (2.8)
25 22.5 53.0 82.2 5.71 12.6 38.5
(12.3) (16.7) (11.9) (0.70) (1.5) (4.4)
0 25.4 57.0 86.0 5.66 12.4 38.1
(11.6) (13.5) (8.2) (0.52) (1.1) (3.3)
aData expressed as mean (standard deviation).
bRBC = red blood cells (x 106/mm3); Hgb = hemoglobin (g/dL); Hct = hematocrit (%). tO.01 > p > 0.001 versus controls.
vertebra was observed in fetuses from all groups with
no treatment-related changes in incidence.
Rabbits
The distribution and fate of all mated New Zealand
White rabbits on study are presented in Table 13. There
was an apparent, but not statistically significant in-
crease in spontaneous abortions and deaths at 200 ppm
relative to controls. All dead females were pregnant.
Pregnancy rate at scheduled sacrifice on gd 29 was
equivalent across treatment groups. Clinical observa-
tions (Table 14) included periocular wetness, perinasal
wetness and discharge, red fluid on tray, and stained fur
as possible treatment-related clinical signs.
Reduced maternal body weight at gd 15 was seen at
200 ppm, but there were no significant weight gain
depressions in any exposure group relative to controls
(Table 15).
Hematologic determinations (Tables 16 and 17) indi-
cated no apparent treatment-related changes in any
parameter evaluated. Statistically significant increases
in hemoglobin content and hematocrit were seen at 100
ppm but not at 200 ppm.
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The only treatment-related change in maternal organ
weights was a reduction in gravid uterine weight at 200
ppm (Table 18). Evaluation ofreproductive parameters
(Table 19) indicated a significant reduction in number of
total implants and viable implants per litter at 200 ppm
relative to controls. There were no treatment-related
effects on the number of nonviable implants, pre-
implantation loss, percent live fetuses, sex ratio or male
and female fetal body weight per litter.
The type and incidence of malformations and varia-
tions observed in rabbit fetuses are presented in Tables
20 and 21, respectively. There was no statistically
significant increase in the number offetuses or oflitters
with one or more affected fetuses with pooled external,
visceral, skeletal or total malformations in any treat-
ment group relative to controls. For individual malfor-
mations, there was an increase in the number of
Table 17. Erythrocyte indices for NZW rabbit does exposed
to EGBE by inhalation on gestational days 6-18.
Tar-get
concentration,
ppm
200
100
50
25
0
Am3s
68.6
[0.9]
67.8
[2.0]
67.1
[1.0]
67.4
[1.2]
67.3
[1.1]
Erythrocyte indicesa
MCH,
pg
22.4
(0.8)
22.1
(0.9)
22.0
(0.8)
22.1
(0.7)
22.0
(0.6)
MCHC,
g/dLc
32.4
(0.4)
32.5
(0.6)
32.7
(0.6)
32.7
(0.6)
32.6
(0.4)
'MCV = mean corpuscular volume (pLm3); MCH = mean corpus-
cularhemoglobin(pg);MCHC = meancorpuscularhemoglobinconcen-
tration (g/dL).
bMedian [quartile deviation].
CMean (standard deviation).
litters at 100 ppm with one or more fetuses exhibiting
fusion of papillary muscles in the left ventricle relative
to controls. Five fetuses in 4 litters out of 19 litters
examined exhibited this malformation at 100 ppm.
There was no concentration-response, i.e., no other
fetuses at any other exposure group exhibited this
malformation (Table 20). This malformation was there-
fore not considered treatment-related.
Variations seen in rabbit fetuses are presented in
Table 21. There was a significant reduction in unossified
sternebra 6 and in rudimentary rib at the first lumbar
vertebra, bilaterally, both at 200 ppm relative to
controls. Except for these two findings, there were no
treatment-related changes in the incidence or type of
variations found across treatment groups. Rudimentary
rib or extra rib was seen across all groups at relatively
high frequency with no exposure-related incidence.
Discussion
The present study, evaluating the effects of EGBE
administered by inhalation during organogenesis, indi-
cates that EGBE produces maternal and embryo/fetal
toxicity in Fischer 344 rats at 100 and 200 ppm, and
maternal toxicity and embryotoxicity but no fetal toxic-
ity in New Zealand White rabbits at 200 ppm. No
teratogenicity was seen in either species at any of the
exposure concentrations employed. In rats at 100 and
200 ppm, the finding of maternal hematuria and/or
hemoglobinuria seen early in the exposure period and
evidence ofanemia confirms and extends the work done
previously in rats (13,14). The reduced red blood cell
count, elevated hemoglobin and hematocrit, increased
cell size and increased hemoglobin per cell found at
sacrifice in rats at 100 and 200 ppm are consistent with
destruction of mature erythrocytes and release of
immature and/or youngerythrocytes into the peripheral
circulation (13,15). Increased absolute and relative
Table 18. Maternal organ weights of NZW rabbits exposed to EGBE by inhalation.
EGBE target exposure concentrations, gestational days (gd) 6-18
200 ppm 100 ppm 50 ppm 25 ppm 0 ppm
Maternal body weight
(gd 29), g 3994.4 ± 426.0a 4163.5 ± 445.3 4047.7 ± 154.9 4314.7 ± 502.7 4363.1 t 455.0
Organ weights, g
Uterus 440.83 ± 99.84* 417.43 ± 187.89 540.20 ± 120.40 526.62 ± 103.07 567.87 ± 157.00
Liver 83.92 ± 11.94 97.52 ± 21.99 88.12 ± 16.80 93.21 ± 17.25 95.53 ± 21.25
Relative liver, %b 2.37 ± 0.32 2.64 ± 0.54 2.51 ± 0.36 2.45 t 0.42 2.52 t 0.48
Thymus 3.57 ± 1.96 2.82 ± 1.10 3.17 ± 1.60 3.30 ± 1.47 3.89 ± 2.21
Relative thymus, %b 0.10 ± 0.05 0.08 ± 0.03 0.09 ± 0.04 0.09 ± 0.04 0.10 ± 0.05
Spleen 1.45 ± 0.30 1.66 ± 0.91 1.66 ± 0.70 1.51 ± 0.42 1.72 ± 0.75
Relative spleen, %b 0.04 ± 0.01 0.04 ± 0.02 0.05 ± 0.02 0.04 ± 0.01 0.04 ± 0.02
Kidney 17.13 ± 2.03 19.19 ± 3.13 17.24 ± 2.45 18.20 ± 2.17 18.96 ± 2.96
Relative kidney, %b 0.48 ± 0.06 0.52 ± 0.07 0.49 ± 0.05 0.48 ± 0.06 0.50 ± 0.05
aValues represent mean ± standard deviation.
bRelative organ weight = organ weight expressed as percent of corrected body weight.
*p < 0.05 compared to control.
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Table 19. Reproductive toxicity evaluation of NZW rabbits exposed to EGBE by inhalation.
EGBE target exposure concentrations, gestational days (gd) 6-18
Corpora lutea
Tbtal implants
Viable implants
Nonviable implants
Embryonic
resorptions
Embryonic
resorptions with
placenta
Dead and macerated
fetuses
Live fetuses, %
Preimplantation loss, %
Sex ratio
Fetal body weights, g
Male
Female
200 ppm
10.1 + 2.1a
8.4 ± 1.9*
7.2 ± 2.4*
1.2 ± 1.7
0.1 ± 0.4
0.9 ± 1.7
0.2 ± 0.6
85.8 ± 20.0
16.0 ± 11.8
58.4 ± 13.1
39.7 ± 6.6
39.2 ± 6.0
100 ppm
11.3 t 2.7
9.0 t 3.3
7.6 t 3.4
1.4 t 2.7
0.0 ± 0.0
0.8 ± 2.7
0.6 ± 0.9
83.5 ± 28.7
22.2 ± 27.0
58.8 ± 21.9b
39.6 ± 64d
38.7 ± 7.1g
50 ppm
10.5 ± 2.5
9.2 ± 2.7
8.5 ± 2.2
0.7 ± 1.6
0.0 ± 0.0
0.3 ± 1.1
0.5 ± 0.9
94.0 ± 11.8
13.2 ± 15.2
48.9 ± 17.4
41.4 ± 6.1l
41.6 ± 6.7
25 ppm
10.8 + 2.9
9.5 ± 2.3
8.4 ± 3.0
1.1 ± 2.1
0.0 ± 0.0
0.3 ± 0.5
0.8 ± 2.1
88.3 ± 20.9
12.4 ± 14.1
52.5 ± 16.1c
40.6 ± 4.9'
40.5 ± 6.4'
aValues represent mean + standard deviation.
bN = 19- One pregnant female had only nonviable uterine implantation sites.
CN = 22 - One pregnant female had only nonviable uterine implantation sites.
dOne rabbit was found gravid at C-section with one embryonic resorption with placenta only (N = 19).
eOne rabbit had only female fetuses (N = 21).
'One rabbit was found gravid at C-section with 10 dead and macerated fetuses only (N = 22).
gTwo rabbits had only male fetuses and one rabbit had an embryonic resorption with placenta only (N = 17).
hOne rabbit had only male fetuses (N = 19).
*p < 0.05 versus controls.
Table 20. Malformations observed in NZW rabbit fetuses exposed to EGBE in utero.a
Fetusesb Littersc
0 ppm 25 ppm 50 ppm 100 ppm 200 ppm 0 ppm 25 ppm 50 ppm 100 ppm 200 ppm
EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE
Number examined
externallyd 181 195
Imperforate anus
No. 0 0
So (0.0) (0.0)
Severelyshortenedtail
No. 0 0
% (0.0) (0.0)
Gastroschisis
No. 0 0
% (0.0) (0.0)
Malrotated limb
No. 0 0
% (0.0) (0.0)
Midfacial hypoplasia
No. 0 1
So (0.0) (0.5)
Shortened limbs
No. 0 1
% (0.0) (0.5)
Number examined
viscerallye 94 102
Papillary muscles in left ventricle fused
No. 0 0
% (0.0) (0.0)
Papillary muscles in right ventricle fused
No. 1 0
% (1.1) (0.0)
Right atrioventricular valve not closed
No. 0 0
% (0.0) (0.0)
187 152 108 20 22 22 19 15
0 0 1 0 0 0 0 1
(0.0) (0.0) (0.9) (0.0) (0.0) (0.0) (0.0) (6.7)
0 0 2 0 0 0 0 2
(0.0) (0.0) (1.9) (0.0) (0.0) (0.0) (0.0) (13.3)
0 0 1 0 0 0 0 1
(0.0) (0.0) (0.9) (0.0) (0.0) (0.0) (0.0) (6.7)
1 0 0 0 0 1 0 0
(0.5) (0.0) (0.0) (0.0) (0.0) (4.5) (0.0) (0.0)
0 0 0 0 1 0 0 0
(0.0) (0.0) (0.0) (0.0) (4.5) (0.0) (0.0) (0.0)
0 0 0 0 1 0 0 0
(0.0) (0.0) (0.0) (0.0) (4.5) (0.0) (0.0) (0.0)
100 81 59 20 22 22 19
0 5 0 0 0 0 4*
(0.0) (6.2) (0.0) (0.0) (0.0) (0.0) (21.1)
2 2 2 1 0 2 2
(2.0) (2.5) (3.4) (5.0) (0.0) (9.1) (10.5)
0 1 0 0 0 0 1
(0.0) (1.2) (0.0) (0.0) (0.0) (0.0) (5.3)
15
0
(0.0)
2
(13.3)
0
(0.0)
0 ppm
11.7 ± 2.1
9.8 ± 3.2
9.0 ± 2.9
0.8 ± 1.2
0.1 ± 0.4
0.3 ± 0.8
0.4 ± 0.9
93.4 ± 9.6
17.3 ± 24.1
58.2 ± 15.0
41.8 ± 6.3
40.1 ± 6.0h
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Table 20. (continued)
Fetusesb Littersc
0 ppm 25 ppm 50 ppm 100 ppm 200 ppm 0 ppm 25 ppm 50 ppm 100 ppm 200 ppm
EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE
Left carotid branches and off innominate
No. 0 1 0 0 0 0 1 0 0 0
% (0.0) (1.0) (0.0) (0.0) (0.0) (0.0) (4.5) (0.0) (0.0) (0.0)
Small constricted pulmonary artery, channel to aorta from rt. ventricle, extra branches off aorta, vestigal rt. ventricle, absent tricuspid
valve and associated papillary muscles
No. 0
% (0.0)
Excessive fluid within pericardium
No. 0
% (0.0)
Ventricular septal defect
No. 1
% (1.1)
Ventricular walls of heart thin
No. 0
% (0.0)
Missing papillary muscle(s)
No. 1
% (1.1)
Two urinary bladders
No. 0
% (0.0)
Fused ureters
No. 0
% (0.0)
Horseshoe kidney (same fetus
No. 0
% (0.0)
Hydronephrosis, right
No. 0
% (0.0)
Hydronephosis, bilateral
No. 0
% (0.0)
Liver misshapen
No. 0
% (0.0)
Liver necrotic (same fetus as a
No. 0
% (0.0)
Midfacial hypoplasia (repeat)
No. 0
% (0.0)
Number examined
skeletallyf 87
Cervical centra fused
No. 0
% (0.0)
as a
abov
0
(0.0)
0
(0.0)
0 1
(0.0) (1.0)
0 0
(0.0) (0.0)
0 0
(0.0) (0.0)
0 0
(0.0) (0.0)
0 0
(0.0) (0.0)
0 0
(0.0) (0.0)
tbove)
0 0
(0.0) (0.0)
0 0
(0.0) (0.0)
4 0
(3.9) (0.0)
0 0
(0.0) (0.0)
,e)
0 0
(0.0) (0.0)
1 0
(1.0) (0.0)
93 87
0 0
(0.0) (0.0)
0 1 0
(0.0) (1.7) (0.0)
0
(0.0)
0
(0.0)
3
(3.7)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
1
(1.2)
1
(1.2)
0
(0.0)
0
(0.0)
0
(0.0)
71
0
(0.0)
Cervical centra malaligned
No. 0 0 0 0
% (0.0) (0.0) (0.0) (0.0)
Cervical centra irregularly shaped (same fetus as above)
No. 0 0 0 0
% (0.0) (0.0) (0.0) (0.0)
Cervical arches irregularly shaped (same fetus as above)
No. 0 0 0 0
% (0.0) (0.0) (0.0) (0.0)
Cervical vertebrae malaligned (same fetus as above)
No 0 0 0 0
% (0.0) (0.0) (0.0) (0.0)
Caudal vertebrae fused (same fetus as above)
No. 0 0 0 0
% (0.0) (0.0) (0.0) (0.0)
Cervical rib (bilateral)
No. 0 0 0 0
% (0.0) (0.0) (0.0) (0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
1
(1.7)
1
(1.7)
1
(1.7)
0
(0.0)
1
(1.7)
1
(1.7)
1
(1.7)
0
(0.0)
49
1
(2.0)
1
(2.0)
1
(2.0)
1
(2.0)
1
(2.0)
1
(2.0)
1
(2.0)
0
(0.0)
1
(5.0)
0
(0.0)
1
(5.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
20
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0 0
(0.0) (0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
2
(9.1)
0
(0.0)
0
(0.0)
1
(4.5)
22
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
1
(4.5)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
22
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0 1
(0.0) (6.7)
0
(0.0)
0
(0.0)
2
(10.5)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
1
(5.3)
1
(5.3)
0
(0.0)
0
(0.0)
0
(0.0)
189
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0 O
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
1
(6.7)
1
(6.7)
1
(6.7)
0
(0.0)
1
(6.7)
1
(6.7)
1
(6.7)
0
(0.0)
15
1
(6.7)
1
(6.7)
1
(6.7)
1
(6.7)
1
(6.7)
1
(6.7)
1
(6.7)
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Table 20. (continued)
Fetusesb Littersc
0 ppm 25 ppm 50 ppm 100 ppm 200 ppm 0 ppm 25 ppm 50 ppm 100 ppm 200 ppm
EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE
Duplication of clavicle
No. 0 0 0 1 0 0 0 0 1 0
So (0.0) (0.0) (0.0) (1.4) (0.0) (0.0) (0.0) (0.0) (5.6) (0.0)
Missing cervical centra
No. 0 0 0 1 0 0 0 0 1 0
% (0.0) (0.0) (0.0) (1.4) (0.0) (0.0) (0.0) (0.0) (5.6) (0.0)
Thoracic centra malaligned
No. 0 0 1 0 0 0 0 1 0 0
% (0.0) (0.0) (1.1) (0.0) (0.0) (0.0) (0.0) (4.5) (0.0) (0.0)
Thoracic centra fused (same as fetus above)
No. 0 0 1 0 0 0 0 1 0 0
% (0.0) (0.0) (1.1) (0.0) (0.0) (0.0) (0.0) (4.5) (0.0) (0.0)
Thoracic arches malaligned (same as fetus above)
No. 0 0 1 0 0 0 0 1 0 0
So (0.0) (0.0) (1.1) (0.0) (0.0) (0.0) (0.0) (4.5) (0.0) (0.0)
Thoracic-12 fused to lumbar-1 centra and arch
No. 0 1 0 0 0 0 1 0 0 0
% (0.0) (1.1) (0.0) (0.0) (0.0) (0.0) (4.5) (0.0) (0.0) (0.0)
Rib branched
No. 1 0 0 0 0 1 0 0 0 0
% (1.1) (0.0) (0.0) (0.0) (0.0) (5.0) (0.0) (0.0) (0.0) (0.0)
All ribs poorly developed
No. 0 0 0 0 1 0 0 0 0 1
% (0.0) (0.0) (0.0) (0.0) (2.0) (0.0) (0.0) (0.0) (0.0) (6.7)
Total malformations
Externald
No. 0 1 1 0 3 0 1 1 0 2
% (0.0) (0.5) (0.5) (0.0) (2.8) (0.0) (4.5) (4.5) (0.0) (13.3)
Viscerale
No. 2 6 3 11 6 2 4 3 7 5
% (2.1) (5.9) (3.0) (13.6) (10.2) (10.0) (18.2) (13.6) (36.8) (33.3)
Skeletalf
No. 1 1 1 2 4 1 1 1 2 3
% (1.1) (1.1) (1.1) (2.8) (8.2) (5.0) (4.5) (4.5) (11.1) (20.0)
Ibtal
No. 3 7 5 13 10 3 5 5 7 7
% (1.7) (3.6) (2.7) (8.6) (9.3) (15.0) (22.7) (22.7) (36.8) (46.7)
aA single fetus may be represented more than once in listing individual defects.
bOnly live fetuses were examined for malformations.
CIncludes litters with one or more malformed fetuses.
dAll fetuses were examined externally.
'Approximately 50% of each litter were examined viscerally (3), and for soft tissue craniofacial malformations.
'Approximately 50% of each litter were examined for skeletal malformations after staining with Alizarin Red S.
90ne litter contained only one live fetus. By convention this fetus was subjected to visceral and craniofacial examination.
p < 0.05 versus controls, Fisher's exact test (two-tailed).
Table 21. Variations observed in NZW rabbit fetuses exposed to EGBE in utero.a
Fetusesb Littersc
0 ppm 25 ppm 50 ppm 100 ppm 200 ppm 0 ppm 25 ppm 50 ppm 100 ppm 200 ppm
EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE
Number examined
externallyd 181 195 187 152 108 20 22 22 19 15
Ecchymoses, limbs
No. 10 2 13 5 15 3 2 6 4 3
% (5.5) (1.0) (7.0) (3.3) (13.9) (15.0) (9.1) (27.3) (21.1) (20.0)
Ecchymoses, head
No. 11 6 20 14 6 4 3 9 7 4
% (6.1) (3.1) (10.7) (9.2) (5.6) (20.0) (13.6) (40.9) (36.8) (26.7)
Ecchymoses, trunk
No. 3 3 18 4 8 3 3 9 3 4
% (1.7) (1.6) (9.6) (2.6) (7.4) (15.0) (13.6) (40.9) (15.8) (26.7)
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Table 21. (continued)
Fetusesb Littersc
0 ppm 25 ppm 50 ppm 100 ppm 200 ppm 0 ppm 25 ppm 50 ppm 100 ppm 200 ppm
EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE
Placental membrane filled with red fluid
No. 0 0 0
% (0.0) (0.0) (0.0)
Placental membrane filled with yellow fluid
No. 0 0 0
% (0.0) (0.0) (0.0)
Right hind leg extended
No. 0 1 2
% (0.0) (0.5) (1.1)
Right hind leg inverted
No. 0 0 1
% (0.0) (0.0) (0.5)
Umbilical cord split
No. 0 1 0
% (0.0) (0.5) (0.0)
Number examined
viscerally 94 102 100
Spleen misshapen
No. 0 1 0
% (0.0) (1.0) (0.0)
Accessory spleen
No. 1 3 1
% (1.1) (2.9) (1.0)
Spleen short
No. 0 0 0
% (0.0) (0.0) (0.0)
Red masses attached to gall bladder membrane
No. 3 6 2
% (3.2) (5.9) (2.0)
Liver discolored
No. 1 0 0
% (1.1) (0.0) (0.0)
Liver nodule
No. 1 0 0
% (1.1) (0.0) (0.0)
Liver, reticular pattern
No. 1 0 0
% (1.1) (0.0) (0.0)
Stomach wall, red in color
No. 0 0 0
% (0.0) (0.0) (0.0)
Excessive fat
No. 1 0 0
% (1.1) (0.0) (0.0)
Thymus hemorrhagic
No. 0 2 0
% (0.0) (2.0) (0.0)
Body cavity filled with milky white fluid
No. 1 0 0
% (1.1) (0.0) (0.0)
Kidney discoloration, left milky white fluid
No. 0 0 1
% (0.0) (0.0) (1.0)
Renal pelvis dilation
No. 0 0 1
% (0.0) (0.0) (1.0)
Heart indented and/or darkened at apex
No. 0 1
% (0.0) (1.0)
Papillary muscle(s) in right ventricle shortened
No. 3 1
% (3.2) (1.0)
Papillary muscle(s) in left ventricle shortened
No. 0 0
% (0.0) (0.0)
1
(1.0)
0
(0.0)
0
(0.0)
2 0 0
(1.3) (0.0) (0.0)
1 0 0
(0.7) (0.0) (0.0)
0 0 0
(0.0) (0.0) (0.0)
0 0 0
(0.0) (0.0) (0.0)
0 0 0
(0.0) (0.0) (0.0)
81 59 20
0 1 0
(0.0) (1.7) (0.0)
1 0 1
(1.2) (0.0) (5.0)
1 0 0
(1.2) (0.0) (0.0)
1 2 3
(1.2) (3.4) (15.0)
0 0 1
(0.0) (0.0) (5.0)
0 0 1
(0.0) (0.0) (5.0)
0 0 1
(0.0) (0.0) (5.0)
0 1 0
(0.0) (1.7) (0.0)
0 0 1
(0.0) (0.0) (5.0)
2 0 0
(2.5) (0.0) (0.0)
0 0 1
(0.0) (0.0) (5.0)
1 0 0
(1.2) (0.0) (0.0)
0 0 0
(0.0) (0.0) (0.0)
1 2 0
(1.2) (3.4) (0.0)
2 1 3
(2.5) (1.7) (15.0)
3 0 0
(3.7) (0.0) (0.0)
0
(0.0)
0
(0.0)
1
(4.5)
0
(0.0)
1
(4.5)
22
1
(4.5)
2
(9.1)
0
(0.0)
5
(22.7)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
2
(9.1)
0
(0.0)
0
(0.0)
0
(0.0)
1
(4.5)
1
(4.5)
0
(0.0)
0 1 0
(0.0)
0
(0.0)
1
(4.5)
1
(4.5)
0
(0.0)
22
0
(0.0)
1
(4.5)
0
(0.0)
2
(9.1)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
1
(4.5)
1
(4.5)
1
(4.5)
0
(0.0)
0
(0.0)
(5.3)
1
(5.3)
0
(0.0)
0
(0.0)
0
(0.0)
19
0
(0.0)
1
(5.3)
1
(5.3)
1
(5.3)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
1
(5.3)
0
(0.0)
1
(5.3)
0
(0.0)
1
(5.3)
2
(10.5)
2
(10.5)
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
15
1
(6.7)
0
(0.0)
0
(0.0)
2
(13.3)
0
(0.0)
0
(0.0)
0
(0.0)
1
(6.7)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
2
(13.3)
1
(6.7)
0
(0.0)
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Table 21. (continued)
Fetuses' Littersc
0 ppm 25 ppm 50 ppm 100 ppm 200 ppm 0 ppm 25 ppm 50 ppm 100 ppm 200 ppm
EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE EGBE
Red markings on heart
No.
Atria engorged
No.
Atria discolored
No.
%I
Fetal atelectasis
No.
Pulmonary artery largei
No.
%I
Granulation in nasal pas
No.
%
White substance in nasa
No.
%
Cochlea dark
No.
%
Indentations on soft an
No.
Gap between skull plate
No.
Lateral ventricles dilate
No.
Number examined
skeletally'
Rudimentary rib lumba:
No.
Rudimentary rib lumba
No.
Extra rib lumbar-1, uni
No.
Extra rib lumbar-1, bik
No.
Sternebra #5, poorly o:
No.
Sternebra #6, poorly o:
No.
%I
Sternebra #5, unossifie
No.
%
Sternebra #6, unossifie
No.
surface
1 0 0 0 0 1 0
(1.1) (0.0) (0.0) (0.0) (0.0) (5.0) (0.0)
0 0 0 0 1 0 0
(0.0) (0.0) (0.0) (0.0) (1.7) (0.0) (0.0)
0 0 0 0 1 0 0
(0.0) (0.0) (0.0) (0.0) (1.7) (0.0) (0.0)
19 17 13 5 9 10 13
'20.2) (16.7) (13.0) (6.2) (15.3) (50.0) (59.1)
r than normal
2 0 1 0 1 1 0
(2.1) (0.0) (1.0) (0.0) (1.7) (5.0) (0.0)
3sage and/or on palate
2 6 9 6 3 2 4
(2.1) (5.9) (9.0) (7.4) (5.1) (10.0) (18.2)
1 passage
4 1 2 0 0 2 1
(4.3) (1.0) (2.0) (0.0) (0.0) (10.0) (4.5)
4 3 3 11 0 2 2
(4.3) (2.9) (3.0) (13.6) (0.0) (10.0) (9.1)
d/or hard palate
0 1 0 0 0 0 1
(0.0) (1.0) (0.0) (0.0) (0.0) (0.0) (4.5)
Ls and skin
0 6 0 1 0 0 1
(0.0) (5.9) (0.0) (1.2) (0.0) (0.0) (4.5)
d (cerebrum)
13 5 7 12 5 8 4
(13.8) (4.9) (7.0) (14.8) (8.5) (40.0) (18.2)
87 93 87 71 49 20 22
r-1, unilateral
18 22 12 11 6 14 15
(20.7) (23.7) (13.8) (15.5) (12.2) (70.0) (68.2)
r-1, bilateral
9 10 4 3 0 6 8
(10.3) (10.8) (4.6) (4.2) (0.0) (30.0) (36.4)
ilateral
10 16 11 6 7 10 10
(11.5) (17.2) (12.6) (8.5) (14.3) (50.0) (45.5)
ateral
36 37 49 35 34 16 16
(41.4) (39.8) (56.3) (49.3) (69.4) (80.0) (72.7)
ssified
32 49 42 30 30 15 21
(36.8) (52.7) (48.3) (42.3) (61.2) (75.0) (95.5)
ssified
35 26 28 17 14 15 15
(40.2) (28.0) (32.2) (23.9) (28.6) (75.0) (68.2)
d
11 6 6 10 7 6 3
(12.6) (6.5)( 6.9) (14.1) (14.3) (30.0) (13.6)
,d
7 9 9 3 0 6 5
(8.0) (9.7) (10.3) (4.2) (0.0) (30.0) (22.7)
0 0 0
(0.0)
0
(0.0)
0
(0.0)
8
(36.4)
1
(4.5)
3
(13.6)
2
(9.1)
2
(9.1)
0
(0.0)
0
(0.0)
4
(18.2)
22
11
(50.0)
3
(13.6)
10
(45.5)
19
(86.4)
19
(86.4)
14
(63.6)
4
(18.2)
5
(22.7)
(0.0)
0
(0.0)
0
(0.0)
4
(21.1)
0
(0.0)
4
(21.1)
0
(0.0)
3
(15.8)
0
(0.0)
1
(5.3)
9
(47.4)
189
7
(38.9)
3
(16.7)
6
(33.3)
17
(94.4)
14
(77.8)
9
(50.0)
6
(33.3)
2
( 1.1)
(0.0)
1
(6.7)
1
(6.7)
5
(33.3)
1
(6.7)
1
(6.7)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
2
(13.3)
15
6
(40.0)
0*
(0.0)
7
(46.7)
14
(93.3)
14
(93.3)
9
(53.3)
4
(26.7)
0*
(0.0)
aA single fetus may be represented more than once in listing individual defects.
bOnly live fetuses were examined for defects.
CIncludes litters with one or more affected fetuses.
dAll fetuses were examined externally.
eApproximately 50% of each litter were examined viscerally (3), and for soft tissue craniofacial defects (4,6).
fApproximately 50% of each litter were examined for skeletal defects after staining with Alizarin Red S. Only those parameters whose
incidence was significantly different from that of controls (p < 0.05, Fisher's exact test) and related parameters are indicated.
90ne litter contained only one live fetus. By convention this fetus was subjected to visceral and craniofacial examination.
*p < 0.05 versus controls, Fisher's exact test (two-tailed).
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spleen weights and relative kidney weight at 200 ppm in
rats also indicate stimulation ofhematopoiesis. That the
homeostatic mechanisms of compensation were not
entirely successful is indicated by the significant reduc-
tion in mean corpuscular hemoglobin concentration
seen at 100 and 200 ppm.
The early rat conceptus appeared vulnerable to insult
by EGBE since 9 of25 dams pregnant at sacrifice at 200
ppm had totally resorbed litters, 7 of 9 detected only
after staining of the uteri. This embryotoxic effect is
responsible for the significant elevations in nonviable
implants and resorptions and the reduction in viable
(i.e., live) fetuses at scheduled necropsy at 200 ppm,
and occurred in the presence ofmaternal toxicity. Fetal
body weights were unaffected by treatment but feto-
toxicity was indicated by the increased incidence of
poorly ossified orunossified skeletal elements seen in gd
21 fetuses. These skeletal districts were those examined
by Aliverti et al. (16), who suggested that retardation of
skeletal ossification, especially on gd 21 in rats, pro-
vided a reliable index ofdelayed development in terato-
genicity studies. Khera (17) has interpreted reductions
in ossification as indications of toxicity and suggested
that the gd 21 fetal skeleton is the most uniform and
therefore the most appropriate to examine.
Khera (17) included as fetal "aberrations" retarda-
tions, variations and deviations. He includes supernu-
merary ribs as a fetal variation, a designation also
followed in this study which demonstrated this finding
across allgroups. Heart and great vesselmalformations,
seen with increased frequency after exposure of rats
to ethylene glycol monomethyl and monoethyl ether
(18,19) were not seen with increased frequency in
this study. The lack of teratogenicity in the presence
of maternal toxicity in rats after exposure to EGBE,
seen in this study, was also reported briefly by Nelson
et al. (18).
New Zealand White rabbit does exhibited toxicity to
EGBE at 200 ppm. Treatment-related increases in
maternal deaths and spontaneous abortions, depressed
body weight during the exposure period and some
relatively nonspecific clinical signs were observed at
this exposure concentration. Embryotoxicity was indi-
cated by reduced gravid uterine weight and a concomi-
tant reduction in total and viable fetuses at scheduled
sacrifice only at 200 ppm. No evidence of fetal toxicity
was observed at any exposure concentration (i.e., no
treatment-related reduction in fetal body weight, no
increase in malformations or variations, including re-
duced ossification in skeletal elements). Supernumerary
ribs, presenting as rudimentary or extra ribs, and
observed across all groups, is the most commonly
occurring skeletal variation in New Zealand White
rabbits (20).
Conclusions
The present study indicates that inhalation exposure
to EGBE at 100 ppm (rats) or 200 ppm (rats and
rabbits) during organogenesis results in maternal toxic-
ity and toxicity to the conceptus (embryotoxicity in rats
and rabbits; fetotoxicity in rats), but no teratogenicity.
Exposure to 100 ppm (rabbits), 50, or 25 ppm (rats and
rabbits) results in no observable maternal, embryo or
fetal toxicity.
Addendum
Analysis of the data generated from the five to six
rats per exposure group exposed one additional day (gd
16) to EGBE indicated the same profile of maternal
toxicity: clinical signs, decreased weight and weight
gains during exposure, elevated relative spleen weights,
decreased food and water consumption and evidence of
anemia. With the small number oflitters in each group,
no alterations in status ofimplantation sites were seen.
Only one fetal malformation was observed: missing
median lung lobe at 25 ppm. Fetal variations seen were
similar to those reported herein, i.e., treatment-related
reduced ossification of skeletal districts, and rudimen-
tary rib and/or bone island at the first lumbar vertebra
distributed across all treatment groups.
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